Amgen and Zai Lab have announced positive topline Phase 3 clinical trial results for bemarituzumab, a monoclonal antibody targeting Fibroblast Growth Factor Receptor 2b (FGFR2b), in the treatment of first-line gastric cancer. The trial, known as FORTITUDE-101 (NCT05052801), demonstrated that bemarituzumab combined with chemotherapy improved overall survival compared to chemotherapy alone in patients with FGFR2b-positive advanced gastric cancer. These findings were highlighted during recent oncology conferences, including the European Society for Medical Oncology Gastrointestinal Cancer Congress (ESMOGI 2025), where experts also discussed biomarker-driven strategies and precision medicine approaches in gastrointestinal cancers. Additional research updates presented at ESMOGI covered metastatic colorectal cancer treatments and hepatocellular carcinoma studies, emphasizing the evolving landscape of targeted therapies in oncology.